Using iKnowMed™ Capabilities

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

To Include BLENREP in Regimens, Send Ophthalmic Exam Notifications, and Monitor Patients' Results

BLENREP is available only through a restricted program called the BLENREP REMS because of the risk of ocular toxicity.

Notable requirements of the BLENREP REMS include the following:

Prescribers must be certified in the BLENREP REMS by enrolling and completing training. Prescribers must counsel patients receiving BLENREP on the risk of ocular toxicity, the need for monitoring via ophthalmic exams before each dose, and provide patients with the BLENREP REMS Patient Guide. Patients must be enrolled in the BLENREP REMS and adhere to monitoring. Healthcare settings that dispense BLENREP must be certified in the BLENREP REMS by enrolling and must obtain authorization prior to dispensing. Wholesalers and distributors must distribute BLENREP only to certified healthcare settings.

Further information is available at www.BLENREPREMS.com and 1-855-690-9572.

INDICATION

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

- **BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.**
- **Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.**
- **Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).**

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

About This Guide

This electronic health record (EHR) guide is intended to help healthcare providers (HCPs) use iKnowMed™ capabilities to facilitate accurate prescribing for BLENREP. It includes steps and examples for adding BLENREP to Regimens, automating notifications for HCPs and patients about REMS requirements, the need for ophthalmic exams and complete blood count (CBC) tests as directed in the USPI, and customizing Flowsheets to capture and monitor patients' overall ophthalmic exam results grading which can be used to inform BLENREP treatment decisions in line with the USPI.

This guide does not constitute guidance for treatment or medical advice. It is the HCP's responsibility to select a treatment based on their independent medical judgment and the needs of each individual patient.

The examples and instructions listed in this guide are based on the most recent version of iKnowMed. Locations, illustrations, and terminology are subject to change with system updates. This guide is meant to serve as an overview only and should not replace detailed instructions provided to you by your internal or external EHR support resources. GSK makes no claims or warranties about the applicability or appropriateness of this information. This guide has not been reviewed or endorsed by iKnowMed or McKesson Specialty Health Technology Products, LLC. GSK does not endorse or recommend any EHR system.

Use the links in the table of contents below or the tabs on each page to navigate this guide.

Table of Contents

INDICATION

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

- **BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.**
- **Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.**
- **Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).**

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Updating a Regimen to Include BLENREP

When new information or data become available, oncology practices may update or create Regimens that include administration instructions as well as necessary tests such as ophthalmic exams and REMS requirements (i.e., completed and submitted Patient Status Form before each dose of BLENREP and obtaining authorization to dispense for all doses). Regimens help care teams facilitate care by grouping together clinical actions that will be administered to a patient during multiple encounters over a specific time frame.

Prescribers must be certified in the BLENREP REMS by enrolling and completing training at www.BLENREPREMS.com. Healthcare settings that dispense BLENREP must be certified in the BLENREP REMS by enrolling at www.BLENREPREMS.com and must obtain authorization prior to dispensing BLENREP. If the practice has an existing Regimen for multiple myeloma and is certified in the BLENREP REMS, BLENREP can be added as a treatment option.

NOTE: *The specific Regimen components listed below are for illustrative purposes only.*

Steps for Updating an Existing Regimen

1. Navigate to **Manage**, select **Regimen Templates**, and select the desired template.
2. In **Search/Add Orderables**, search for and select the desired orderable item, such as BLENREP, and select **Save** to add to the template.
3. Select **BLENREP** from the template.
4. From the BLENREP details window, select details that will default when an order is placed.
5. Check **Rx** and **Formula Dose** to enter appropriate dosing instructions. Use the **Quick SIG Pick** or **Show Drug Forms** to display preset Dose, Frequency, and Form Instruction options. Select as appropriate.
6. Select **SAVE** to save the updated Regimen Template.
7. Repeat steps 1 and 2 to search for, select, and add other Orderable Items to the Regimen Template, as appropriate and aligned to REMS requirements.



Illustrative example of Treatment Template in Flowsheet (recreated from iKnowMed)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS

Ocular Toxicity

BLENREP causes ocular toxicity, defined as changes in the corneal epithelium and changes in BCVA based on ophthalmic exam (including slit lamp exam), or other ocular adverse reactions as defined by the CTCAE.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Regimen to Include BLENREP

Regimens help care teams facilitate care by grouping together clinical actions that will be administered to a patient during multiple encounters over a specific time frame.

The following steps provide an overview of the process for creating a new multiple myeloma Regimen to include BLENREP.

Steps for Creating a New Regimen

1. From the **Manage** menu, select **Regimen Templates**.
2. In the **Reference Name** or **Display Name** field, search for and select the Regimen to copy, such as A Blank Regimen Template.



illustrative example of a Regimen Template search (recreated from iKnowMed)

3. Select **Copy Regimen**.
4. Enter the new Reference Name (internal) and the Display Name.
5. Select **Save**.
6. Search for and select the problems for which the additional regimen is appropriate (e.g., Multiple Myeloma).
7. Define Regimen Rule detail; select **Save**.
8. Select **Add Rule**.
9. Complete the **Regimen Details**, including the appropriate Regimen Type.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

In DREAMM-7, ocular toxicity occurred in 92% of patients, including Grade 3 or 4 in 77% of patients. The most common ocular toxicities (>25%) were reduction in BCVA (89%) and corneal exam findings (86%) based on ophthalmic exam findings, blurred vision (66%), dry eye (51%), photophobia (47%), foreign body sensation in eyes (44%), eye irritation (43%), and eye pain (33%).

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Regimen to Include BLENREP (cont.)

Steps for Creating a New Regimen (cont.)

10. Select **Save** to complete the Regimen information before editing the medication information.
11. From the appropriate **Treatment Group**, select the **+** on the right side of the treatment group.
12. In **Search/Add Orderables**, search for and select the desired orderable item, such as BLENREP, and select **Save** to add to the template.
13. Select **BLENREP** from the template.
14. From the BLENREP details window, select details that will default when an order is placed.
15. Check **Rx** and **Formula Dose** to enter appropriate dosing instructions. Use the **Quick SIG Pick** or **Show Drug Forms** to display preset Dose, Frequency, and Form Instruction options. Select appropriate dosing instructions in line with the USPI.
16. Select **SAVE**.
17. Repeat steps 11 and 12 to search for, select, and add other Orderable Items to the Regimen Template, as appropriate and aligned to REMS requirements.



Illustrative example of entering Regimen details (recreated from iKnowMed)

Include the BLENREP REMS Eye Care Professional Exam Form available at **www.BLENREPREMS.com** as part of the BLENREP Regimen. The form should be completed by the patient's optometrist or ophthalmologist and sent (via eFax, Fax, EMR, or by the patient) to the oncologist at the close of the patient's eye exam to give the oncologist time to determine appropriate treatment dosing prior to administration of BLENREP. If supported, work with your EHR IT team to add the form as a custom document.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Ocular toxicity based on ophthalmic exam findings was reported as Grade 2 in 9% of patients, Grade 3 in 56% of patients, and Grade 4 in 21% of patients. The median time to onset of the first Grade 2 to 4 ophthalmic exam findings was 43 days (range: 15 to 611 days). The median duration of all Grade 2 to 4 ophthalmic exam findings was 85 days (range: 5 to 813 days). Patients experienced a median of 3 episodes (range: 1 to 11 episodes) of ocular toxicity based on ophthalmic exam findings. Of the patients with Grade 2 to 4 ophthalmic exam findings, 42% had improvement of the last event to Grade 1 or better; 25% had resolution of the last event based on return to baseline or normal ophthalmic exam findings.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating Automated Patient Chart Alerts

This workflow allows HCPs to draft and set up Patient Outreach Campaigns that are delivered to the patient via the patient portal. By adding Patient Chart Alerts to a BLENREP Regimen, patients who are prescribed BLENREP will automatically receive a patient portal message with a reminder to complete requirements prior to administration of BLENREP, including patient enrollment in the BLENREP REMS to document that they were counseled and agree to adhere to ophthalmic monitoring, required ophthalmic exams, completed BLENREP REMS Eye Care Professional Exam Form, etc.

Patient communications are managed via the Ontada Health Patient Portal in iKnowMed™. Forms can be created as templates for information to be sent to the patient. A prerequisite for this workflow is that a form be created for BLENREP Treatment Follow-up containing the information regarding required prerequisite care, such as REMS enrollment, REMS counseling, compliance with ophthalmic monitoring, and an ophthalmic exam.

Steps for Creating Chart Alerts for Patients Prescribed BLENREP and Sending a Patient Notification Form

1. Access **Ontada Health** tab.
2. Click the **Bulk Actions** icon.
3. Click **SEND FORMS**.
4. Click **Select Patients**.
5. Use the **Filter** fields to select **Patients** to send forms to, such as Filter by Patient.
6. Use the **Filter** fields to find **Forms** to send. Filter by Name, such as BLENREP Appointment Reminder.
7. Check the box for the desired form. The selected form is added under Included Forms.
8. Click **CONFIRMATION**.
9. Validate the **Selected Patients** and **Selected Forms** to ensure accuracy.
10. Click **CONFIRM AND SEND** to send the form to the patient.



Illustrative example of sending Patient Form for BLENREP Treatment Follow-up (recreated from iKnowMed)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

The most commonly reported corneal exam findings included superficial punctate keratopathy, microcyst-like deposits, epithelial changes, and haze. Cases of corneal ulcer, including cases with infection, have been reported and should be managed promptly by an eye care professional.

A reduction in BCVA to 20/50 or worse in at least one eye occurred in 69% of patients, including 29% who experienced a change in BCVA to 20/100 or worse, and 12% who experienced a change in BCVA to 20/200 or worse. Of the patients with reduced BCVA to 20/50 or worse in at least one eye, 61% had resolution of the last event to baseline or better. Of the patients with reduced BCVA to 20/100 or worse, 57% had resolution of the last event. Of the patients with reduced BCVA to 20/200 or worse, 48% had resolution of the last event.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating Automated HCP Inbox Messages

iKnowMed™ allows HCPs to draft and set up silent notifications called Inbox Messages. These Inbox Messages could include a reminder to verify prescriber REMS certification and patient REMS enrollment, complete a BLENREP REMS Eye Care Professional Exam Form, submit a Patient Status Form before each dose of BLENREP, obtain authorization to dispense, or to follow up with patients prior to upcoming infusions to ensure that they have completed their required ophthalmic exams and CBC tests. Additionally, an Inbox Message may be used to remind HCPs about ordering labs or checking REMS requirements such as prescriber certification, patient enrollment, dispensing healthcare setting certification, completed and submitted Patient Status Form, authorization code prior to dispensing, etc.

To manage the BLENREP REMS process, a To-Do List can be created in iKnowMed. Using the To-Do List, tasks (To-Dos) associated with BLENREP treatment can be assigned to appropriate practice staff. Each task remains on the assignee's To-Do List until the task is completed.

Steps for Creating a Group Inbox Message on the To-Do List

1. From the **Messages** tab, select the **To-Do** widget to display the To-Do List.
2. Select the **Message Center** tab, then select **Practice Messages**.
3. Select **Compose** to create a new To-Do.
4. Select a **Recipient** using **To** search.
5. Enter a **Subject**.
6. Use **Regarding patient(s)** to search for and select a **Patient**.
7. Use **Message Body** to enter the details of the To-Do.
8. Select **SEND** to send the To-Do to the appropriate practice staff.



Illustrative example of adding details to a To-Do task (recreated from iKnowMed)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Ophthalmic exams (including slit lamp exam and BCVA assessment) should be conducted by an eye care professional, such as an ophthalmologist or optometrist, at baseline, before each dose of BLENREP, promptly for new or worsening symptoms, and as clinically indicated. Perform baseline exam within 4 weeks prior to the first dose. Perform each follow-up exam within 10 days prior to the next planned dose. All effort should be made to schedule the exam as close to BLENREP dosing as possible. Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less and resume at same or reduced dose or permanently discontinue based on severity.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Flowsheet to Document Ocular Adverse Reaction Severity Grade

Flowsheets are templates used for documentation and can be customized to capture the patient's ophthalmic exam results (conducted by either optometrists or ophthalmologists) before administration of BLENREP. Storing exam results within a Flowsheet can provide clinicians with an aggregated view of a patient's eye health and any vision changes over time. Because each Flowsheet entry must be tied to a Lab Result, a Lab Order for ocular adverse reaction severity must first be set up in iKnowMed™ as a Data Element(s).

Data Element(s) used to document a patient's ocular adverse reaction severity grade can be set up in the context of **Lab Results** in iKnowMed. A prerequisite for this workflow is to have a **Lab Order** set up for ocular adverse reaction severity testing. The setup of a new Lab Order must be requested from iKnowMed technical support. A Lab Order is necessary because each result must be associated with an order.

Steps for Documenting an Ocular Adverse Reaction Severity Grade as a Lab Result

1. Access the **Results** tab.
2. Click the **Results Entry** tab.
3. Search for and **select** the lab, such as Ophthalmology Testing.
4. On the **Results** pane, click **ALLOW TEXT ENTRY** and enter the result for the selected test in the **Result** field.
    a. Ensure the Grades listed correspond to the listed severity grades for Ophthalmic Examination Findings as outlined in the Prescribing Information

Recommended Dosage Modifications for Ocular Toxicity based on Ophthalmic Exam Findings[1]	
Grade 1	Continue treatment at current dosage.
Grade 2	Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. Resume treatment at Reduced Dosage Level 1 as per Table 1. If recurrent Grade 2 or 3 ocular toxicity is experienced, resume treatment at Reduced Dosage Level 2.
Grade 3	Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. Resume treatment at Reduced Dosage Level 1 as per Table 1. If recurrent Grade 2 or 3 ocular toxicity is experienced, resume treatment at Reduced Dosage Level 2.
Grade 4	Consider permanent discontinuation of BLENREP. If continuing treatment, withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. For patients previously on 2.5 mg/kg every 3 weeks, resume treatment at Reduced Dosage Level 1 as per Table 1. For patients previously on 1.9 mg/kg every 3 weeks, resume treatment at Reduced Dosage Level 2. If recurrent Grade 4 ocular toxicity is experienced, permanently discontinue BLENREP.

For more information on grading definitions and dose modifications for ocular toxicity and non-ocular adverse reactions, please see the full Prescribing Information.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Counsel patients to promptly inform their healthcare provider of any ocular symptoms. Counsel patients to use preservative-free artificial tears at least 4 times a day starting with the first infusion and continuing until the end of treatment, and to avoid wearing contact lenses for the duration of therapy. Bandage contact lenses may be used under the direction of an eye care professional.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Flowsheet to Document Ocular Adverse Reaction Severity Grade (cont.)

Steps for Creating an Ocular Adverse Reaction Severity Flowsheet to Document Ocular Adverse Reaction Severity Grade

1. Access the **Flowsheet** tab.
2. To customize the Flowsheet, click ⚙ on the right side of the screen.
3. In **Show Flowsheet Categories for this patient**, check the box for **Lab Results**.
4. In the Flowsheet, in the section entitled **Lab Other**, the Ocular Adverse Reaction Severity Grade displays.



Illustrative example of Flowsheet customization (recreated from iKnowMed)



Illustrative example of Ocular Adverse Reaction Severity Grade displayed in Flowsheet (recreated from iKnowMed)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Changes in visual acuity may be associated with difficulty for driving and reading. Counsel patients to use caution when driving or operating machinery.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating an Auto Text to View or Document Ocular Adverse Reaction Severity Grade

An Auto Text phrase, or Macro, can be created to insert documented grading based on ophthalmic exam results into visit notes. Auto Text phrases are shortcuts that insert predefined text into patient notes, discharge instructions, or other documentation using an abbreviated phrase. By typing a period (.) followed by the phrase, the predefined text associated with that phrase is automatically inserted.

iKnowMed™ does not support the ability for the practice to add Macros. Practices can contact iKnowMed technical support and request that a new Macro be added.

The request for BLENREP Ocular Adverse Reaction Severity Grade macros to be added should include the **Dose modifications for ophthalmic examination findings Chart** in line with the USPI.



Illustrative example of Ocular Reaction Severity Grade Macros in Template Note (recreated from iKnowMed)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

BLENREP Risk Evaluation and Mitigation Strategy (REMS)

BLENREP is available only through a restricted program called the BLENREP REMS because of the risk of ocular toxicity.

Further information is available at www.BLENREPREMS.com and 1-855-690-9572.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Thrombocytopenia

Thrombocytopenia of any grade occurred in 100% of patients in DREAMM-7.

Grade 2 thrombocytopenia occurred in 10% of patients, Grade 3 in 29% of patients, and Grade 4 in 45% of patients. Clinically significant bleeding (Grade ≥2) occurred in 7% of patients with concomitant low platelet levels (Grade 3 or 4).

Monitor complete blood cell counts at baseline and periodically during treatment as clinically indicated. Withhold or reduce the dose of BLENREP based on severity.

Embryo-fetal Toxicity

Based on its mechanism of action, BLENREP can cause fetal harm when administered to a pregnant woman because it contains a genotoxic compound (the microtubule inhibitor, monomethyl auristatin F [MMAF]) and it targets actively dividing cells.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with BLENREP and for 4 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BLENREP and for 6 months after the last dose.

ADVERSE REACTIONS

The most common adverse reactions (≥20%) with BLENREP in combination with bortezomib and dexamethasone are reduction in BCVA, corneal exam findings, blurred vision, dry eye, photophobia, foreign body sensation in eyes, eye irritation, upper respiratory tract infection, hepatotoxicity, eye pain, diarrhea, fatigue, pneumonia, cataract and COVID-19.

The most common Grade 3 or 4 (≥10%) laboratory abnormalities are decreased platelets, decreased lymphocytes, decreased neutrophils, increased gamma-glutamyl transferase, decreased white blood cells, and decreased hemoglobin.

Reference: 1. BLENREP. Prescribing Information. GSK; 2025.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

PMUS-BLMBRGD250007 October 2025
Produced in USA.

BLENREP belantamab mafodotin-blmf for injection 70 mg